Myeloid derived IL-33 controls Treg responses during parasite infection
骨髓源性 IL-33 控制寄生虫感染期间的 Treg 反应
基本信息
- 批准号:10317582
- 负责人:
- 金额:$ 39.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-06 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAnti-Inflammatory AgentsAntigen-Presenting CellsAutomobile DrivingB-LymphocytesBiologicalCell LineageCell ShapeCellsCellular StructuresChronicConfocal MicroscopyCre driverDataDefectDendritic CellsDevelopmentDiseaseEpithelialEpithelial CellsEquilibriumFOXP3 geneGATA3 geneGastrointestinal tract structureGene Expression ProfileGenetic TranscriptionHelminthsHomeostasisHumanIleitisImmuneImmunityImmunosuppressionInfectionInflammationInflammation MediatorsInflammatoryInflammatory ResponseInterferon Type IIInterleukin-1Interleukin-17InterleukinsIntestinesLymphocyte SubsetLymphoidLymphoid CellMaintenanceMass Spectrum AnalysisMusMyelogenousNatural ImmunityNatural regenerationOralOrganOrphanOutcomePTPNS1 geneParasitesParasitic infectionPathogenicityPathologicPopulationPredispositionProductionProtozoan InfectionsPublishingRegulationRegulatory T-LymphocyteReportingResistanceRetinoic Acid ReceptorRoleSourceT cell responseTestingTissuesToxoplasma gondiiToxoplasmosisVaccine TherapyXCR1 geneadaptive immunitycytokinedysbiosisexperimental studygastrointestinalgut microbiotahelminth infectionimmunopathologyinflammatory disease of the intestineintestinal cryptintestinal epitheliumintestinal homeostasismacrophagemembermicrobialmicroscopic imagingpathogenreceptorresidenceresponsetissue repairtranscription factortranscriptome sequencingvaccination strategy
项目摘要
Project Summary
The interleukin 1 (IL-1) cytokine superfamily member IL-33 drives host protection against gastrointestinal (GI)
pathogens through mechanisms that remain unclear. Paradoxically, IL-33 responsiveness in different
lymphocyte subsets dictates its pro- vs. anti-inflammatory roles evinced by its ability to promote expansion of
group 2 innate lymphoid cells (ILC2) or Foxp3+ regulatory T cells (Tregs), respectively. Whether source of IL-33
influences its biological role has been largely ignored due the current paradigm that IL-33 is only released from
damaged structural cells (e.g. epithelial cell lineages). However, our recently published data show that intestinal
epithelial cell (IEC)-derived IL-33 drives ILC2 responses and GI helminth immunity, whereas dendritic cell (DC)-
derived IL-33 drives ST2+Foxp3+ Treg responses and helminth susceptibility. This proposal seeks to understand
the mechanisms responsible for IL-33 expression and production in the myeloid lineage and further investigates
whether IL-33 cellular context controls the balance between inflammation vs. immunosuppression during
protozoan infections as it does in helminth infections. Our project tests the central hypothesis that cellular
source of IL-33 determines whether IL-33 serves a protective or pathogenic role during GI parasite
infection through controlling intestinal Treg subset expansion. We will test this hypothesis in two specific
aims (SA). Experiments proposed in SA1 will: a) transcriptionally profile IL-33+ vs. IL-33- DC to determine whether
IL-33 expressing APC constitute a distinct subset, b) employ microscopy and imaging mass spectrometry to
understand the tissue niches where these cells reside, and c) determine whether DC-derived IL-33 is critical for
the maintenance and/or induction of distinct subsets of Foxp3+ Treg through microbial-dependent mechanisms.
SA2 will generate mice that allow IL-33 deletion in distinct DC-subsets and tissue macrophage populations to
determine their impact on intestinal tissue homeostasis and host protection against GI pathogens. Lastly, we will
determine whether epithelial vs. myeloid derived-IL-33 controls microbial dysbiosis and the pathological outcome
following oral Toxoplasma gondii infection. Taken together, this project seeks to expand the basic understanding
of how the cellular context of cytokine production impacts immunity against important human GI pathogens.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
De'Broski R Herbert其他文献
De'Broski R Herbert的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('De'Broski R Herbert', 18)}}的其他基金
Central role for skin sensory neurons in anti-helminth immunity
皮肤感觉神经元在抗蠕虫免疫中的核心作用
- 批准号:
10665391 - 财政年份:2023
- 资助金额:
$ 39.57万 - 项目类别:
Neuronal regulation of sinonasal Type 2 inflammation
鼻窦 2 型炎症的神经元调节
- 批准号:
10740468 - 财政年份:2023
- 资助金额:
$ 39.57万 - 项目类别:
Myeloid derived IL-33 controls Treg responses during parasite infection
骨髓源性 IL-33 控制寄生虫感染期间的 Treg 反应
- 批准号:
10463791 - 财政年份:2021
- 资助金额:
$ 39.57万 - 项目类别:
Perforin 2 controls unconventional cytokine release from mucosal APC
穿孔素 2 控制粘膜 APC 的非常规细胞因子释放
- 批准号:
10629434 - 财政年份:2021
- 资助金额:
$ 39.57万 - 项目类别:
Perforin 2 controls unconventional cytokine release from mucosal APC
穿孔素 2 控制粘膜 APC 的非常规细胞因子释放
- 批准号:
10283046 - 财政年份:2021
- 资助金额:
$ 39.57万 - 项目类别:
Myeloid derived IL-33 controls Treg responses during parasite infection
骨髓源性 IL-33 控制寄生虫感染期间的 Treg 反应
- 批准号:
10662289 - 财政年份:2021
- 资助金额:
$ 39.57万 - 项目类别:
Perforin 2 controls unconventional cytokine release from mucosal APC
穿孔素 2 控制粘膜 APC 的非常规细胞因子释放
- 批准号:
10472644 - 财政年份:2021
- 资助金额:
$ 39.57万 - 项目类别:
Trefoil factor proteins regulate inflammation and immunity
三叶因子蛋白调节炎症和免疫
- 批准号:
10179207 - 财政年份:2020
- 资助金额:
$ 39.57万 - 项目类别:
Physiological roles of schistosome TRP ion channels with atypical pharmacology
血吸虫 TRP 离子通道的生理作用与非典型药理学
- 批准号:
10078843 - 财政年份:2017
- 资助金额:
$ 39.57万 - 项目类别:
Trefoil factor proteins regulate inflammation and immunity
三叶因子蛋白调节炎症和免疫
- 批准号:
9170097 - 财政年份:2016
- 资助金额:
$ 39.57万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 39.57万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 39.57万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 39.57万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 39.57万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 39.57万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 39.57万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 39.57万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 39.57万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 39.57万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 39.57万 - 项目类别:














{{item.name}}会员




